HOME PAGE Chi siamo Normativa di Riferimento Formazione News
HOME PAGE
Chi siamo
Normativa di Riferimento
Formazione
News
Guest Book
Newsletter
Publications
Riservato SOCI
Iscrizione e Rinnovi
Contatti
 
 

Poster AIEOP 2016:
Cagnazzo C, Arizio F, Pirondi S,Taverniti C, Frati P, Monti M, Gentili G, Campora S on behalf of Gruppo Italiano Data Manager


Poster AIOM 2016
E. Marchesi1, M. Monti2, S. Campora3, G. Gentili2, P. Frati4, S. Pirondi5, C. Taverniti6, C. Cagnazzo7 (on behalf of GIDM)



Poster AIOM 2015:
Campora S., Arizio F., Ferretti E., Morabito S., Taverniti C., Marchetti F., Dall’Agata M., Frati P., McMahon L.,Ragazzini A., Cagnazzo C., on behalf of Gruppo Italiano Data Manager


Poster AIOM 2014: 
McMahon L. Cagnazzo C. Campora S. Dall’Agata M. Frati P. Ragazzini A. on behalf of Gruppo Italiano Data
Manager

Annals of Oncology 25: 17501755, 2014 doi:10.1093/annonc/mdu205 Published online 6 June 2014. A PHASE I DOSE ESCALATION TRIAL OF TREMELIMUMAB (CP-675,206) IN COMBINATION WITH GEMCITABINE IN CHEMOTHERAPY-NAIVE PATIENTS WITH METASTATIC PANCREATIC CANCER. M. Aglietta, C. Barone, M. B. Sawyer, M. J. Moore, W. H. Miller, Jr, C. Bagalà, F. Colombi, C. Cagnazzo, L. Gioeni, E. Wang, B. Huang, K. D. Fly & F. Leone

Critical Reviews in Oncology/Hematology 85 (2013) 136–148. BILIARY TRACT CARCINOMAS: FROM CHEMOTHERAPY TO TARGETED THERAPY. Donatella Marino, Francesco Leone, Giuliana Cavalloni, Celeste Cagnazzo, Massimo Aglietta

PANITUMUMAB IN COMBINATION WITH INFUSIONAL OXALIPLATIN AND ORAL CAPECITABINE FOR CONVERSION THERAPY IN PATIENTS WITH COLON CANCER AND ADVANCED LIVER METASTASES. The MetaPan Study. Francesco Leone; Salvatore Artale; Donatella Marino; Celeste Cagnazzo; Stefano Cascinu; Carmine Pinto; Giuseppe Fornarini; Marco Tampellini; Francesca Di Fabio; Andrea Sartore-Bianchi; Luciano De Carlis; Raffaele Pugliese; Lorenzo Capussotti; Luisa Gioeni; Salvatore Siena; and Massimo Aglietta.

J Ovarian Res. 2012 Jun 25;5(1):17. doi: 10.1186/1757-2215-5-17. A CASE SERIES OF LOW DOSE BEVACIZUMAB AND CHEMOTHERAPY IN HEAVILY PRETREATED PATIENTS WITH EPITHELIAL OVARIAN CANCER. Defferrari C1, Campora S, D'Amico M, Piccardo A, Biscaldi E, Rosselli D, Pasa A, Puntoni M, Gozza A, Gennari A, Zanardi S, Lionetto R, Bandelloni M, Decensi A.

Expert Opin Drug Saf. 2014 Nov;13(11):1437-42. doi: 10.1517/14740338.2014.960388. Epub 2014 Sep 16. AN OBSERVATIONAL STUDY OF NASAL CAVITY TOXICITY IN CANCER PATIENTS TREATED WITH BEVACIZUMAB. D'Amico M1, Pagano M, Pasa A, Puntoni M, Clavarezza M, Gennari A, Gozza A, Zanardi S, Defferrari C, Provinciali N, Campazzi E, Campora S, Paleari L, Marra D, Petrera M, DeCensi A.

Urol Int. 2014;92(3):276-81. doi: 10.1159/000353414. Epub 2013 Oct 19. AGE IS PREDICTIVE OF IMMEDIATE POSTOPERATIVE URINARY CONTINENCE AFTER RADICAL RETROPUBIC PROSTATECTOMY. Campodonico F1, Manuputty EE, Campora S, Puntoni M, Maffezzini M.

HEMANGIOBLASTOMA OF THE GASTROINTESTINAL TRACT. Andrea Casadei Gardini, Federica Pieri, Pietro Fusaroli, Alessandro Passardi, Manlio Monti, Paola Rosetti, Sebastiano Calpona, Martina Valgiusti, Angela Ragazzini, Marianna Ricci, Giovanni Luca Frassineti .

HEMANGIOBLASTOMA OF THE GASTROINTESTINAL TRACT: A FIRST CASE. Andrea Casadei Gardini, MD, Federica Pieri, MD,Pietro Fusaroli, MD, Devil Oboldi MD, Alessandro Passardi, MD,Manlio Monti, MD, Paola Rosetti, MD, Sebastiano Calpona, MD, Martina Valgiusti, MD, Angela Ragazzini BScDino Amadori, MD, and Giovanni Luca Frassineti, MD

RISK SHARING IN CANCER CARE: AN ITALIAN CANCER CENTER EXPERIENCE Angela Ragazzini, Valentina Di Iorio, Carla Masini, Mattia Marri, Martina Minguzzi, Dino Amadori, Oriana Nanni

IPILIMUMAB EXPANDED ACCESS PROGRAMME (EAP): 0% OF CLINICAL BENEFIT IN  EVALUABLE ADVANCED MELANOMA PATIENTS. Stefania V.L. Nicoletti, Massimo Guidoboni, Laura Ridolfi,Alberto Farolfi, Alessandro, Passardi, Linda Valmorri, Angela Ragazzini, Ruggero Ridolfi.

EPIDEMIOLOGICAL PATTERNS OF ENDEMIC BURKITT’S LYMPHOMA IN NORTHERN TANZANIA Alberto Farolfi, Nestory Masalu, Gerardo Musuraca, Patrizia Serra, Angela Ragazzini, Lucas Faustine, Dino Amadori, on behalf of Associazione Vittorio Tison

KRAS, BRAF and PIKCA Status in Squamous Cell Anal Carcinoma (SCAC). Andrea Casadei Gardini, Laura Capelli., Paola Ulivi., Massimo Giannini, Eva Freier, Stefano Tamberi, Emanuela Scarpi, Alassandro Passardi, Wainer Zoli, Angela Ragazzini, Dino Amadori, Giovanni Luca Frassineti

DETECTION AND RECOVERY OF CIRCULATING COLON CANCER CELLS USING A DIELECTROPHORESIS-BASED DEVICE: KRAS MUTATION STATUS IN PURE CTCS. Francesco Fabbri, Silvia Carloni, Wainer Zoli, Paola Ulivi, Giulia Gallerani, Pietro Fici, Elisa Chiadini, Alessandro Passardi, Giovanni L. Frassineti, Angela Ragazzini, Dino Amadori

PREDICTIVE ROLE OF MULTIPLE GENE ALTERATIONS IN RESPONSE TO CETUXIMAB IN METASTATIC COLORECTAL CANCER: A SINGLE CENTER STUDY. Running title: Multiple marker analysis in mCRC. Paola Ulivi, Laura Capelli, Martina Valgiusti, Wainer Zoli, Emanuela, Scarpi, Elisa Chiadini, Paola Rosetti, Sara Bravaccini, Luca Saragoni, Andrea Casadei Gardini, Angela Ragazzini, Daniele Calistri, Giovanni, Luca Frassineti, Dino Amadori and Alessandro Passardi

Distante V, Mano MP, Ponti A, Cataliotti L, Filippini L, Giorgi D, Lazzaretti MG, Marchesi C, Perfetti E, Segnan N; GISMa Group. MONITORING SURGICAL TREATMENT OF SCREEN-DETECTED BREAST LESIONS IN ITALY. "2nd European Breast Cancer Conference" Brussels 26-30 sett . 2000. Eur J Cancer 2000; 36(Suppl 5): S123 abstract n° 396 Eur J Cancer. 2004 May;40(7):1006-12

Giacomin A, Preto L, Perfetti E, Vercellino PC, Roselli B THE CANCER REGISTER OF BIELLA PROVINCE: INCIDENCE AND MORTALITY DATA. In “Cancer incidence in five continents (Vol VIII)”Parkin DM, Whelan SL, Ferlay J, Raymond L, Teppo L, Thomas BD (Eds). IARC Scientific. Publication nº 155, Lyon 2002.

Fabbri S, Perfetti E, Covoni D,Bianchi S,Brancato B,Paci E and the GISMa Epidemiologist Working Group
Benign breast diseases in breast cancer screening programs in italy (2000-2001). Tumori 2004 Nov-Dec;90(6):547-9. Impact Factor of 1.09

Dal Molin A, Guerretta L, Perfetti E , Rasero L, Clerico M.  THE LATE COMPLICATIONS OF TOTALLY IMPLANTABLE CENTRAL VENOUS ACCESS PORTS: THE RESULTS FROM ITALIAN MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY. ONF. 2010- 0086  Eur J Oncol Nurs. 2010 Dec 15. Impact Factor of 1.79


Ripamonti C.I., Prandi  C, Costantini M, Perfetti E, Pellegrini F, Marco Visentin M, Lorenza Garrino L, Anna De Luca A, Maria Adelaide Pessi M A and Carlo Peruselli. THE EFFECTIVENESS OF THE QUALITY PROGRAM PAC-IFICO TO IMPROVE PAIN MANAGEMENT IN HOSPITALIZED CANCER PATIENTS: A BEFORE-AFTER CLUSTER PHASE II TRIAL: THE LAUNCH OF BMC PALLIATIVE CARE. BMC Palliative Care, 13:15 (29 Mar 2014)

 



logoMedio


VS




2013

The Burden of Clinical Trials
Feasibility of the OPAL rating tool to assess clinical trial complexity



2012
EVALUATION OF THE READABILITY OF INFORMATION AND CONSENT FORMS FOR CANCER CLINICAL TRIALS AND RESEARCH IN ITALY



2011
THE 2011 SURVEY FROM THE GRUPPO ITALIANO DATA MANAGERS (G.I.D.M.)





logoMedio

VS




2011
DATA MANAGERS WANTED. ANALYSIS OF PUBLIC NOTICE FOR ANNOUNCEMENTS AT ITALIAN PUBBLIC HOSPITALS. CONTRACTS, REQUIREMENTS, REMUNERATION, AND CRITICALITIES











Site Map